0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Thalidomide's Back in the News, but in More Favorable Circumstances

Teri Randall
JAMA. 1990;263(11):1467-1468. doi:10.1001/jama.1990.03440110019002.
Text Size: A A A
Published online

ABSTRACT

RESEARCHERS ARE taking a second look at what is perhaps the most notorious and stigmatized drug in the recent history of drug therapy: thalidomide.

Once marketed as a sleeping pill, the drug is blamed for nearly 12 000 birth defects in the late 1950s, some 10 000 of these in the Federal Republic of (West) Germany alone.

No other pharmaceutical has provoked such dramatic changes in the drug regulatory process around the world—a reputation that could have precluded its therapeutic use forever. But a series of chance events followed by an extensive body of research has uncovered a new side to the drug that its original manufacturers never imagined: thalidomide is a potent immunosuppressive that lacks the toxic side effects of steroids.

This other side to thalidomide was discovered serendipitously by Israeli dermatologist J. Sheskin, MD, at Rothchild Hadassah University Hospital, Jerusalem, in 1965. He treated six of his lepromatous

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();